Early access
Sign in
CompletedNo phase

Low Molecular Weight hEparin vs. Aspirin Post-partum

Key facts

Who runs it
Mount Sinai Hospital, Canada
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
29 Aug 2021
Ended
1 Mar 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prophylactic low molecular weight heparin
  • Low molecular weight heparin and low-dose aspirin
Record updated
17 June 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Personal history of unprovoked VTE prior to pregnancy or hormone associated VTE and not prescribed therapeutic anticoagulation or
  • Family history (1st degree relative) of VTE and antithrombin deficiency, protein C or protein S deficiency or
  • Combined thrombophilia or homozygous for the factor V Leiden mutation or prothrombin gene mutation, and family history of VTE (1st degree relative) and
  • > 18 years of age

Who cannot take part

  • Contraindication to LMWH, e.g. known allergy
  • Active bleeding at any site, excluding physiological vaginal bleeding
  • Patients with bleeding disorders
  • Known severe hypertension (SBP >200mm/hg and/or DBP >120mm/hg) during the current pregnancy or postpartum
  • Contraindication to ASA:; Known ASA allergy; Documented history of gastrointestinal ulcer; Known platelet count < 50x10\^9/L at any time during the current pregnancy or postpartum
  • Pre-existing indication for therapeutic LMWH

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is single centre pilot, randomized controlled trial assessing postpartum prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin compared to standard of care of prophylactic LMWH for 6 weeks at moderate to high risk of developing VTE.

The 2 groups in the trial

  • Prophylactic Low Molecular Weight Heparin (LMWH)Existing treatment, for comparison

    Prophylactic LMWH for 6 weeks postpartum

    Treatment: Prophylactic low molecular weight heparin

  • Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose AspirinTreatment being tested

    Prophylactic LMWH for 3 weeks followed by low dose Aspirin for 3 weeks.

    Treatment: Low molecular weight heparin and low-dose aspirin

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Publications
Record updated
17 June 2026